March 5, 2021

Articles Azithromycin for Community Treatment of Suspected COVID-19 in People at Increased Risk of an Adverse Clinical Course in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• Use of the antibiotic azithromycin plus usual care did not provide meaningful benefits to recovery time from COVID-19 compared to usual care alone, according to a randomized, placebo-controlled, open-label trial in the UK from May to November 2020. Patients receiving azithromycin plus usual care (n=500) had similar time to recovery compared to patients receiving usual care alone (n=823) (HR=1.08, 95%CI: 0.95-1.23). The probability of a clinically meaningful benefit of at least 1.5 days in time to recovery was 0.23. Both groups had similar rates of hospitalization (3%).

Butler et al. (Mar 4, 2021). Articles Azithromycin for Community Treatment of Suspected COVID-19 in People at Increased Risk of an Adverse Clinical Course in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial. The Lancet. https://doi.org/10.1016/S0140-6736(21)00461-X